@entity7499 is considered essential for proper bone regeneration. The purpose of this investigation was to determine if a combined therapy of @entity2095 ( @entity2095 ) and cartilage oligomeric matrix protein angiopoietin-1 (COMP-Ang1) can potentiate the therapeutic effect of @entity2095 in a @entity35 model of @entity63 @entity39 of the femoral head (INFH). INFH was surgically induced in the femoral head of @entity35 , and the animals were divided into the following groups: 1) a sham-operated group (sham group), 2) a bovine serum albumin-injected group (BSA group), 3) a @entity2095 -injected group ( @entity2095 group), and 4) a COMP-Ang1 and @entity2095 -injected group (COMP-Ang1 + @entity2095 group) (n=20/group). Radiologic, histologic, and histomorphometric assessments were performed to assess femoral head morphology, vascular density, and bone resorption activity. Western blots and immunohistochemical staining were performed to evaluate production of BMP-related signaling proteins in C3H10T1/2 cells and tissues. Real-time RT-PCR was performed to investigate expression of the target integrin gene, and the effect of integrin on C3H10T1/2 cells was determined using a cell adhesion assay. Radiographs obtained six weeks after injection revealed better preservation of the architecture of the femoral head in the COMP-Ang1 + @entity2095 group compared with the BSA and @entity2095 groups. Histological findings indicated increased trabecular bone and vascularity and decreased osteoclast bone resorption activity in the COMP-Ang1 + @entity2095 group compared with those in the BSA and @entity2095 groups. The combination of COMP-Ang1 and @entity2095 increased phosphorylation of @entity68249 , @entity12220 , and Akt. Increased integrin a3 and b1 mRNA expression in the COMP-Ang1 + @entity2095 group promoted cell adhesion. These results suggest that COMP-Ang1 preserved the necrotic femoral head through the potentiation of @entity2095 signaling pathways and angiogenesis. Combination treatment with COMP-Ang1 and @entity2095 may be a clinically useful therapeutic application in INFH.

COMP-Angiopoietin1 Potentiates the Effects of Bone Morphogenic Protein-2 on @entity63 Necrosis of the Femoral Head in XXXX .

@entity68249 :: ('25671;25631;59328', 'Gene') :: ['Smad1/3/5'] @entity7499 :: ('MESH:D016510', 'Disease') :: ['Angiogenesis'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity2095 :: ('29373(Tax:10116)', 'Gene') :: ['bone morphogenetic protein-2', 'BMP-2'] @entity35 :: ('10116', 'Species') :: ['rat', 'rats'] @entity12220 :: ('81649(Tax:10116)', 'Gene') :: ['p38']
@entity35 :: (10116,Species) :: ['Rats']
